Medical Devices and IVD
Medical Devices and IVD
15th November to 16th November 2021,
London, United Kingdom
SMi is proud to announce the launch of their Medical Device and IVD conference to be held in London in November 2021.
The current regulatory environment for medical devices and combination products is facing a significant shift. With the new EU Medical Device and In Vitro Diagnostic Regulations being implemented in May 2021 and May 2022 respectively, what does the future hold for Medical Devices and IVD industry?
SMi's Medical Device and IVD conference will prepare you for the challenging times ahead, navigating the new legislations and how to comply with regulatory requirements with insightful addresses from notified bodies, competent authorities, devices development experts and pharma representation.
Topics of discussion will include the latest updates on the MDR and IVDR, performance evaluations requirements, companion diagnostics key considerations, notified body guidance for a successful submission, quality and risk management systems, and much more…
source: http://www.smi-online.co.uk/pharmaceuticals/uk/conference/Medical-Devices-IVD
If you have any questions about this news, please do not hesitate to contact us.
Join Our Newsletter for Free
Latest News
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT).
LEARN MOREPfizer Acquires Amplyx Pharmaceuticals
Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.
LEARN MOREJanux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials
Janux Therapeutics today announced the closing of a $125 million Series B financing led by RA Capital Management and joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company).
LEARN MORE